1462 related articles for article (PubMed ID: 26520780)
41. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
[TBL] [Abstract][Full Text] [Related]
42. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
[TBL] [Abstract][Full Text] [Related]
43. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
44. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
45. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
Kocher M; Frommolt P; Borberg SK; Rühl U; Steingräber M; Niewald M; Staar S; Stuschke M; Becker G; Fischedick AR; Herfarth K; Grauthoff H; Müller RP
Strahlenther Onkol; 2008 Nov; 184(11):572-9. PubMed ID: 19016015
[TBL] [Abstract][Full Text] [Related]
46. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
Brown PD; Krishnan S; Sarkaria JN; Wu W; Jaeckle KA; Uhm JH; Geoffroy FJ; Arusell R; Kitange G; Jenkins RB; Kugler JW; Morton RF; Rowland KM; Mischel P; Yong WH; Scheithauer BW; Schiff D; Giannini C; Buckner JC;
J Clin Oncol; 2008 Dec; 26(34):5603-9. PubMed ID: 18955445
[TBL] [Abstract][Full Text] [Related]
47. Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.
McNamara MG; Lwin Z; Jiang H; Chung C; Millar BA; Sahgal A; Laperriere N; Mason WP
J Neurooncol; 2014 Mar; 117(1):153-60. PubMed ID: 24469855
[TBL] [Abstract][Full Text] [Related]
48. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
Lai A; Filka E; McGibbon B; Nghiemphu PL; Graham C; Yong WH; Mischel P; Liau LM; Bergsneider M; Pope W; Selch M; Cloughesy T
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1372-80. PubMed ID: 18355978
[TBL] [Abstract][Full Text] [Related]
49. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
[TBL] [Abstract][Full Text] [Related]
50. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
[TBL] [Abstract][Full Text] [Related]
51. Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide.
Peponi E; Tourkantonis I; Tasiou I; Pavlidis N; Pentheroudakis G; Tsekeris P
J BUON; 2014; 19(3):718-23. PubMed ID: 25261658
[TBL] [Abstract][Full Text] [Related]
52. Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Brachman DG; Pugh SL; Ashby LS; Thomas TA; Dunbar EM; Narayan S; Robins HI; Bovi JA; Rockhill JK; Won M; Curran WP
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):961-7. PubMed ID: 25832688
[TBL] [Abstract][Full Text] [Related]
53. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
[TBL] [Abstract][Full Text] [Related]
54. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Herrlinger U; Rieger J; Koch D; Loeser S; Blaschke B; Kortmann RD; Steinbach JP; Hundsberger T; Wick W; Meyermann R; Tan TC; Sommer C; Bamberg M; Reifenberger G; Weller M
J Clin Oncol; 2006 Sep; 24(27):4412-7. PubMed ID: 16983109
[TBL] [Abstract][Full Text] [Related]
55. Accelerated hyperfractionation plus temozolomide in glioblastoma.
Kaul D; Florange J; Badakhshi H; Grün A; Ghadjar P; Exner S; Budach V
Radiat Oncol; 2016 May; 11():70. PubMed ID: 27209069
[TBL] [Abstract][Full Text] [Related]
56. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Sepúlveda JM; Belda-Iniesta C; Gil-Gil M; Pérez-Segura P; Berrocal A; Reynés G; Gallego O; Capellades J; Ordoñez JM; La Orden B; Balañá C
Clin Transl Oncol; 2015 Sep; 17(9):743-50. PubMed ID: 26033428
[TBL] [Abstract][Full Text] [Related]
57. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
58. Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide.
Tieu MT; Lovblom LE; McNamara MG; Mason W; Laperriere N; Millar BA; Ménard C; Kiehl TR; Perkins BA; Chung C
J Neurooncol; 2015 Aug; 124(1):119-26. PubMed ID: 26015297
[TBL] [Abstract][Full Text] [Related]
59. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
[TBL] [Abstract][Full Text] [Related]
60. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.
Sanghera P; Perry J; Sahgal A; Symons S; Aviv R; Morrison M; Lam K; Davey P; Tsao MN
Can J Neurol Sci; 2010 Jan; 37(1):36-42. PubMed ID: 20169771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
